Nanobodies Market

Nanobodies Market, By Product Type (Monovalent Nanobodies, Bivalent Nanobodies, Bispecific Nanobodies, Biparatopic Nanobodies, Multivalent Nanobodies, Fusion Nanobodies), By Therapeutic Area (Oncology, Infectious Diseases, Inflammatory and Autoimmune Diseases, Neurological Disorders, Others), By Application (Therapeutic, Diagnostic, Research), By End User (Hospitals, Biopharmaceutical Companies, Diagnostic Laboratories, Others), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Single-domain antibodies known as "nanobodies" are derived from heavy-chain antibodies in mammals and have special characteristics such as nanoscale size, robust structure, stable and soluble behaviours in aqueous solution, reversible protein folding, high affinity and specificity for only one cognate target, among others. Nanobodies have a variety of applications, ranging from basic science to clinical therapeutics. Due to the small size and single-domain chain, nanobodies have a larger binding surface and lower nonspecific background binding and are used as affinity capture reagents. Furthermore, nanobodies can be used to treat cancer and other diseases by blocking ligand-receptor interactions, such as antagonizing the anti-von Willebrand factor to prevent thrombosis or inhibiting anti-TNF-α to treat arthritis. Nanobodies can also be expressed inside cells and fused with a fluorescent protein to monitor antigen activity. Nanobodies are well suited as protein stabilizers, which is particularly important during the crystallization of a protein. Thus, nanobodies are used in a number of protein crystallization studies due to the ability of nanobodies to lock proteins in a particular conformation stabilize flexible domains. This, increases the adoption of nanobodies and, thereby, drives the growth of the nanobodies market.

Market Dynamics

The key players in the nanobodies market are focusing on the development of new products by investing in research and development to strengthen their product portfolio. Thus, the introduction of such advanced products in the market is expected to drive growth of the global nanobodies market over the forecast period. For instance, in October 2020, Merck KGaA, a global science and technology company, entered into an out-licensing agreement with Novartis AG, a global healthcare company, for the development of M6495, an anti-ADAMTS5 nanobody, for the potential treatment of osteoarthritis (OA). This increased treatment option for osteoarthritis patients.

Key features of the study:

• The report provides an in-depth analysis of the global nanobodies market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for the market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global nanobodies market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of thestudy include Merck KGaA, Sanofi, AlpalifeB Inc, GenScript, Novartis International AG, Taisho Pharmaceutical Holdings Co., Ltd., Sino Biological, Inc., GeneMedi, Biocytogen, Abnova Corporation, NanoTag Biotechnologies, Avillion LLP, Capra Science, Numab Therapeutics, CUSABIO TECHNOLOGY LLC, Proteintech Group, Inc., GT Biopharma, Inc., Confo Therapeutics, R&D Systems, Inc., Abcepta Biotech Ltd. Co.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global nanobodies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nanobodies market

Detailed Segmentation:

• Global Nanobodies Market, By Product Type:
• Monovalent Nanobodies
• Bivalent Nanobodies
• Bispecific Nanobodies
• Biparatopic Nanobodies
• Multivalent Nanobodies
• Fusion Nanobodies
• Global Nanobodies Market, By Therapeutic Area:
• Oncology
• Infectious Diseases
• Inflammatory and Autoimmune Diseases
• Neurological Disorders
• Others
• Global Nanobodies Market, By Application:
• Therapeutic
• Diagnostic
• Research
• Global Nanobodies Market, By End User:
• Hospitals
• Biopharmaceutical Companies
• Diagnostic Laboratories
• Others
• Global Nanobodies Market, By Region:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa
• Company Profiles
• Merck KGaA
• Sanofi
• AlpalifeB Inc
• GenScript
• Novartis International AG
• Taisho Pharmaceutical Holdings Co., Ltd.
• Sino Biological, Inc.
• GeneMedi
• Biocytogen
• Abnova Corporation
• NanoTag Biotechnologies
• Avillion LLP
• Capra Science
• Numab Therapeutics
• CUSABIO TECHNOLOGY LLC
• Proteintech Group, Inc.
• GT Biopharma, Inc.
• Confo Therapeutics
• R&D Systems, Inc.
• Abcepta Biotech Ltd. Co.